Pharmaceutical News

RSS

New treatment improves visual acuity score of patients with retinitis pigmentosa

Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech’s patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.

8 May 2005

New cervical cancer drug could be a bestseller

New data released yesterday says that a new vaccine that promises to protect against cervical cancer could offer wider resistance to the disease than previously thought.

5 May 2005

New Zealand Ministry of Health to consider Vaxigrip vaccine trial results

Pharmac and the New Zealand Ministry of Health are aware that Sanofi-Pasteur has been running a clinical trial to demonstrate the efficacy of their influenza vaccine, Vaxigrip.

4 May 2005

pSivida's BrachySil takes first step in regulatory programme leading to product approval

pSivida Limited has announced that current data from its lead cancer product BrachySil will be presented at this year's European Society for Therapeutic and Radiation Oncology Conference in Budapest on May 5, 2005. The conference is an opportunity to share and validate the Company's promising findings with an international scientific, clinical and industrial audience.

3 May 2005

Boostrix receives FDA approval as treatment for pertussis

GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).

3 May 2005

Promising results from study of Pirfenidone in idiopathic pulmonary fibrosis (IPF) patients

InterMune today announced that the American Journal of Respiratory and Critical Care Medicine (AJRCCM) published results from a double-blind, randomized, placebo-controlled Phase II trial evaluating pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

2 May 2005

Myogen's Ambrisentan granted orphan drug designation by Europeans

Myogen today announced that the Commission of the European Communities, with a favorable opinion of the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA), has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension.

2 May 2005

FDA to change regulations regarding side-effect information in drug ads

The Food and Drug Administration is about to make it easier for you to understand both the benefits and risks of a prescription medication, it was revealed at the Second Annual Medical Liaison Seminar sponsored here by Scientific Advantage LLC.

2 May 2005

GlaxoSmithKline to acquire Corixa Corporation

GlaxoSmithKline has announced the execution of a definitive agreement pursuant to which GSK will acquire Corixa Corporation, a developer of innovative products that regulate immunity, based in Seattle, WA (USA).

2 May 2005

Judge calls GlaxoSmithKline 'high-handed' over legal action from Biota

A Supreme Court judge in Melbourne, Australia has described as "high-handed" the delay by global pharmaceutical firm GlaxoSmithKline (GSK) in filing a defence against legal action from Biota Holdings last Friday.

1 May 2005

FDA gives go-ahead for new diabetes treatment

Sufferers from adult-onset diabetes, the most common form of the disease, will soon be able to access a new injectable diabetes treatment which when used with oral drugs, should be more effective in controlling their blood sugar.

1 May 2005

Generex begins testing new vaccine for breast cancer patients

Generex Biotechnology Corporation announced today that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express as part of the Company's Phase I Trial. The Trial will include between 16 and 24 patients.

28 Apr 2005

SkyePharma and GlaxoSmithKline reach agreement on payment of royalties for Paxil CR

SkyePharma has announced that it has entered into an amendment agreement with GlaxoSmithKline (GSK) in respect of Paxil CR. Under the terms of the amendment agreement, GSK will make a one-time payment of approximately $10 million.

28 Apr 2005

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

27 Apr 2005

America's largest retail pharmacy is moving all over the counter single ingredient pseudoephedrine products behind the counter

Pseudoephedrine is the key precursor ingredient that can be converted into the illegal drug methamphetamine. After careful review of numerous state legislative proposals and law enforcement bulletins, CVS made the decision to move these products behind the counter in all of its 5,400 stores across 36 states over the next sixty days.

27 Apr 2005

Patients' lives at risk from substandard drugs say heart specialists

Global action is needed to counter the dangers of substandard life-saving drugs that are putting patients' lives and health at risk, according to heart specialists writing in the new (19 April) issue of Europe's leading cardiology journal, the European Heart Journal.

27 Apr 2005

Drug adverts are a haphazard approach to health promotion

As California State Assembly Bill 95 (Koretz, D-West Hollywood), designed to reign in drug marketing costs in California by requiring manufacturers of drugs for life-threatening chronic conditions to pay the state a rebate equal to the drug marketing cost, moves to the Assembly Appropriations Committee, AIDS Healthcare Foundation (AHF) -- cites a study and accompanying editorial published today in the Journal of American Medical Association (JAMA) that demonstrates the influence that Direct to Consumer Advertising (DTCA) has on physicians' prescribing decisions.

26 Apr 2005

EU calls for tougher warnings on antidepressants for kids

A committee of experts in Europe are calling for strong warnings to be placed on two classes of antidepressants, informing doctors and parents of the risk they could pose to children and adolescents.

25 Apr 2005

Wide variation in access to HIV medications across states

Twenty-one State AIDS Drug Assistance Programs (ADAPs) report limiting access to their programs in some way, including 11 with waiting lists, despite an increase in the national ADAP budget, according to the ninth annual National ADAP Monitoring Project Report released by the Kaiser Family Foundation and the National Alliance of State AIDS Directors (NASTAD).

23 Apr 2005

International internet drug ring shattered

Drug Enforcement Administration (DEA) Administrator Karen P. Tandy has announced the results of Operation “Cyber Chase”, a year-long Organized Crime Drug Enforcement Task Force (OCDETF) investigation that targeted international Internet pharmaceutical traffickers operating in the United States, India, Asia, Europe and the Caribbean. These e-traffickers distributed drugs world-wide using “rogue” Internet pharmacies.

23 Apr 2005